Patent intelligence · CA
CA 3133787
GELS HOMOGENES INJECTABLES COMPRENANT DE MULTIPLES FORMES D'ACIDE HYALURONIQUE ET LEURS PROCEDES DE FABRICATION
GELS HOMOGENES INJECTABLES COMPRENANT DE MULTIPLES FORMES D'ACIDE HYALURONIQUE ET LEURS PROCEDES DE FABRICATION
Patent details — CA 3133787
- Jurisdiction
- CA
- Status
- granted
- Grant date
- Oct 1, 2020
- Expiration
- Sep 26, 2040
- Applicant
- ALLERGAN PHARMACEUTICALS INT LTD [IE]
- CPC classes
- A61K 8/ 04 A I, A61K 8/ 73 A I, A61K 9/ 00 A I, A61K 31/ 728 A I
Quick answer
CA 3133787 (GELS HOMOGENES INJECTABLES COMPRENANT DE MULTIPLES FORMES D'ACIDE HYALURONIQUE ET LEURS PROCEDES DE FABRICATION) is held by ALLERGAN PHARMACEUTICALS INT LTD [IE]. Status: granted. Granted Oct 1, 2020. Expires Sep 26, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- ALLERGAN PHARMACEUTICALS INT LTD [IE]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 8/ 04 A I, A61K 8/ 73 A I, A61K 9/ 00 A I, A61K 31/ 728 A I, A61K 31/ 738 A I, A61K 47/ 36 A I
More from ALLERGAN PHARMACEUTICALS INT LTD [IE]
Related pharmaceutical patents in our USPTO index.
-
US 12383545
TREATMENT OF MIGRAINE
granted -
US 2025064788
TREATMENT OF MIGRAINE
granted -
US 2024180883
TREATMENT OF MIGRAINE
granted -
WO 2024081718
ANTAGONISTE DU RÉCEPTEUR CGRP POUR LE TRAITEMENT DE LA MIGRAINE
granted -
CA 3244873
TRAITEMENT PRÉVENTIF DE LA MIGRAINE
granted -
WO 2023077094
TRAITEMENT D'UN TROUBLE DÉPRESSIF MAJEUR
granted -
US 2023130736
METHODS OF TREATING MIGRAINE
granted -
US 2022380379
PHARMACEUTICAL COMPOUNDS
granted
Frequently asked questions
What is US patent 3133787?
CA 3133787 (GELS HOMOGENES INJECTABLES COMPRENANT DE MULTIPLES FORMES D'ACIDE HYALURONIQUE ET LEURS PROCEDES DE FABRICATION) is held by ALLERGAN PHARMACEUTICALS INT LTD [IE]. Status: granted. Granted Oct 1, 2020. Expires Sep 26, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.
Who owns CA 3133787?
ALLERGAN PHARMACEUTICALS INT LTD [IE] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 25 pharmaceutical patents for this assignee.
When does CA 3133787 expire?
Our index shows an expiration date of Sep 26, 2040 (14 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.